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ABSTRACT
Introduction: Inflammation of the central nervous
system is increasingly regarded as having a role in
cognitive disorders such as dementia and depression,
but it is not clear how such inflammation relates to
other aspects of neuropathology, structural and
functional changes in the brain and symptoms (as
assessed via clinical and neuropsychological
assessment and MRI). This study will explore these
pathophysiological mechanisms using positron
emission tomography (PET) which allows in vivo
imaging of inflammation, amyloid and τ deposition,
together with neuropsychological profiling, MRI and
peripheral biomarker analysis.
Methods and analysis: Using PET imaging of the
ligand [11C]PK11195, we will test for increased
neuroinflammation in vivo in patients with Alzheimer’s
disease, Lewy body dementia, frontotemporal dementia,
progressive supranuclear palsy, late-onset depression
and mild cognitive impairment, when compared to
healthy controls. We will assess whether areas of
inflammatory change are associated with amyloid and τ
deposition (assessed using 11C-labelled Pittsburgh
Compound B ([11C]PiB) and 18F-labelled AV-1451,
respectively), as well as structural and connectivity
markers found on MRI. Inflammatory biomarker
analysis and immune-phenotyping of peripheral blood
monocytes will determine the correlation between
central inflammation and peripheral inflammation.
Finally, we will examine whether central inflammatory
markers seen on PET imaging are associated with
global and domain specific cognitive impairments or
predict cognitive decline over 12 months.
Ethics and dissemination: The study protocol was
approved by the local ethics committee, East of
England—Cambridge Central Research Ethics
Committee (reference: 13/EE/0104). The study is also
Administration of Radioactive Substances Advisory
Committee (ARSAC) approved as part of this process.
Data will be disseminated by presentation at national
and international conferences and by publication,
predominantly in journals of clinical neuroscience,
neurology and psychiatry.
INTRODUCTION
Over 800 000 people in the UK have
dementia1 for which there are many causes
including Alzheimer’s disease (AD),
Parkinson’s disease dementia (PDD),
dementia with Lewy bodies (DLB), fronto-
temporal dementia (FTD) and progressive
supranuclear palsy (PSP). There are also
many more people with at risk states such as
mild cognitive impairment (MCI) and late
life depression (LLD). Since depression and
dementia have many symptoms in common,
including cognitive impairments and low
Strengths and limitations of this study
▪ Multimodal deep phenotyping.
▪ Comparisons between diseases as well as with
controls.
▪ Longitudinal neuropsychology data.
▪ Comparison of central and peripheral
inflammation.
▪ Unable to assess causation.
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mood, they may also share common neurobiological
substrates.
The Neuroimaging of Inﬂammation in Memory and
Related Other Disorders (NIMROD) project has been
established to test the hypothesis that neuroinﬂamma-
tion plays a pivotal role in the pathogenesis of
different forms of dementia and related disorders.
Neuroinﬂammation describes the cellular and biochem-
ical response to a variety of insults within the central
nervous system (CNS) and includes the activation of
microglia which are the resident macrophages of the
CNS. Microglia provide the innate immune response to
invading pathogens and also initiate the adaptive
response through antigen presentation.2 [11C]PK11195,
a positron emission tomography (PET) ligand that binds
to the translocator protein (TSPO) which is upregulated
on microglia in their activated state, allows the imaging
of neuroinﬂammation in vivo. Other ligands that bind
TSPO have been developed (these include [11C]PBR28,
[11C]DPA713, [11C]DAC and [18F]DPA-714), however
their use is complicated by intersubject variability in
binding afﬁnities to TSPO3 that does not affect [11C]
PK11195, which remains the best characterised and most
widely used ligand. Although afﬁnity is lower than some
second-generation ligands for TSPO, it has the advan-
tage of a well-established robust protocol for synthesis
and analysis and is less affected by genetic variations in
afﬁnity.
There is growing evidence for a link between inﬂam-
mation and depression4 5 and between inﬂammation
and a broad range of neurodegenerative disorders. Such
evidence of neuroinﬂammation is strongest in AD6 and
includes neuropathological studies revealing evidence of
brain inﬂammation and PET imaging displaying micro-
glial activation in vivo7–10 which may well play a protect-
ive role in early disease.11 Animal studies in AD as well
as old age have also found that drugs antagonising the
Leukotriene pathway and thereby modulating inﬂamma-
tion have beneﬁcial effects on cognition.12 13 Similarly,
PET imaging and pathology studies showing evidence of
inﬂammation are emerging in DLB and PDD.14–16 In
vivo inﬂammation has also been shown in MCI, however
results in several studies were conﬂicting.17 In FTD17 18
and PSP19–21 studies of inﬂammation are in their early
stages but are suggestive of a possible increased rate of
chronic neuroinﬂammation.
The deposition of insoluble, misfolded proteins, such
as hyperphosphorylated τ or β amyloid, has long been
recognised as a feature of neurodegenerative disease
such as AD22 and frontotemporal lobar degeneration
which includes FTD and PSP. More recently, analogous
pathological accumulations of α-synuclein in PD,23 and
TAR DNA binding protein 43 (TDP-43) in several forms
of frontotemporal lobar degeneration and motor
neuron disease,24 have been found. In some diseases,
the degree of abnormal protein deposition correlates
with clinical severity and progression, for example using
Braak staging of pathology in AD.25
The ligands to image protein accumulations in vivo
have developed greatly in the last decade. The ﬁrst of
these to make a major impact in research and clinical
practice was the 11C-labelled Pittsburgh compound B
([11C]PiB) for β-amyloid, with 18F-labelled analogues
(ﬂorbetaben, ﬂorbetapir and ﬂutemetamol) being
developed subsequently.26 A range of new compounds
has recently been developed that bind to τ deposits.
These include [18F]AV-1451,27 THK28 and PBB3
ligands.29 [18F]AV-1451 has been examined in post-
mortem studies of Alzheimer’s pathology30 31 with
encouraging results supporting its use in vivo. Recently
published work has correlated [18F]AV-1451 binding
with Braak stage in typical AD32 and distribution of
binding with focal AD syndromes.33 The extent and loca-
tion of [18F]AV-1451 binding in vivo in MAPT mutation
carriers correlated well with extent and distribution of
pathology in the same subject at postmortem34 while
statistically signiﬁcant differences in amount and distri-
bution of binding have been shown between a subject
with a MAPT mutation and healthy older controls.35
There are concerns about ‘off target’ binding of [18F]
AV-1451 to sites such as Neuromelanin36 and Choroid
plexus,37 but these need veriﬁcation. Much work still
needs to be performed to determine speciﬁcity and sen-
sitivity of the [18F]AV-1451 ligand, particularly in non-AD
tauopathies such as FTD and PSP.
Here we use three PET ligands: [11C]PK11195, [11C]
PiB and [18F]AV-1451 in patients with different forms of
dementia, related disorders and controls. Using [11C]
PK11195 PET, we will assess for microglial activation in
vivo in all cohorts (ie, AD, MCI, FTD, LBD, PSP and
LLD). Few studies have investigated microglial activation
in FTD, LBD, PSP and LLD so this key aspect of our
project is novel. We will also compare how the extent
and pattern of microglial activation relates to clinical
symptoms in each of these conditions, separately and
across groups. For example, our study will assess whether
increased microglial activation in the hippocampus is
associated with increased memory symptoms or if visual
hallucinations in DLB are associated with increased
occipital lobe microglial activation.
In addition, all cohorts will be assessed for peripheral
markers of inﬂammation and structural and functional
abnormalities on MRI. This will include immune-
phenotyping to analyse for changes within the adaptive
immune system, as reﬂected by changes in T-cell subsets
as well as serum inﬂammatory markers to identify
changes in both arms of the immune system. Studies in
AD have shown evidence of peripheral inﬂammatory
changes,38 which may well be replicated in other cogni-
tive disorders. Changes in CD4 cells have been recog-
nised in PD, for example.39 40 Structural, vascular and
functional connectivity changes will be analysed using
MRI. Both of these modalities will be compared to
central microglial activation to determine if central
inﬂammation is linked to either in the brain. The rele-
vance of baseline biomarkers to clinical disease
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progression will also be tested through annual follow-up
of participants.
Data obtained from [18F]AV-1451 and/or [11C]PiB
binding (depending on the cohort) will be correlated
with data from [11C]PK11195 PET imaging to look for
areas of overlap between protein deposition and micro-
glial activation. The relationship between microglial acti-
vation and symptomatology will be assessed in the
context of any underlying increased protein deposition.
SUMMARY OF RESEARCH QUESTIONS
1. Is there an increase in microglial activation in each
of AD, DLB, PDD, PSP, FTD, LLD and MCI groups,
compared to age-matched control participants?
2. Does the extent and pattern of any increased micro-
glial activation in these disorders relate to:
A. key clinical symptoms, such as deﬁcits in
memory, attention, motor and visual symptoms
and their relevant cortical areas in each
cohort?
B. peripheral markers of neuroinﬂammation such as
changes in serum cytokines and alterations in
T-cell subsets when compared to participants in
the control group?
C. structural changes on MRI, including atrophy, vas-
cular changes and deﬁcits in white matter tracts
in relevant regions compared to control
participants?
D. alterations in functional connectivity as measured
using resting-state Blood Oxygenation Level
Dependent (BOLD) fMRI compared to control
participants?
E. the extent and pattern of increased brain amyloid
deposition as assessed by [11C]PiB PET in DLB,
PDD and MCI?
3. Is there increased τ deposition, as revealed by [18F]
AV-1451 PET, in AD, PSP, FTD and MCI groups com-
pared to age-matched control participants and does
the extent and pattern of any increased τ deposition
relate to the extent and pattern of microglial
activation?
4. Does the distribution of binding differ between
disease cohorts and from controls as would be pre-
dicted by known anatomical correlates of the clinical
syndromes?
5. Does increased central microglial activation and/or
changes in peripheral markers of inﬂammation
predict subsequent clinical course, including future
cognitive and functional decline?
METHODS AND ANALYSIS
Summary
The observational study protocol consists of neuro-
psychological assessment and neurological examination
with annual reappraisal over 3 years (ﬁgure 1). These
baseline assessments are followed by one visit for MRI
and then one, two or three visits for PET depending on
the cohort. A cerebrospinal ﬂuid (CSF) substudy will be
conducted in smaller numbers consented for this
purpose.
Participants, recruitment and selection
Patient participants are recruited from cognitive dis-
order clinics in neurology, old age psychiatry and
related services at Cambridge University Hospital
(CUH) and other trusts within the region including
Cambridgeshire, Lincolnshire, Bedfordshire, Norfolk,
Suffolk, Hertfordshire and Essex, where participants are
willing to travel to Cambridge for imaging studies. Case
registers held by the Dementias and Neurodegeneration
specialty of the UK Clinical Research Network
(DeNDRoN) and the Join Dementia Research ( JDR)
platform41 are other sources of participants. Control par-
ticipants are recruited from regional healthy adults who
have indicated a willingness to participate in dementia
research via JDR or DeNDRoN. We also recruit inter-
ested, healthy friends and non-blood-related family
members of patients.
Potential participants identiﬁed as above who show
willingness to take part in the research are provided with
information about the study in the form of a patient
information sheet. Following a period of time to con-
sider the information, a follow-up phone call is made to
inquire as to their interest in participation and to ask for
further information to ensure they are eligible to take
part. An appointment is then made at the study prem-
ises or at their home to provide an opportunity to ask
further questions and obtain formal written consent
from the participant or, in cases where the participant
does not have capacity, advice from an appropriate con-
sultee in accordance with the Mental Capacity Act 2005
(England and Wales). Consent is for participation in the
study and publication of ﬁndings.
Eligibility criteria
Participants are to be included in the study if they are
aged over 50 and have sufﬁcient proﬁciency in English
to allow standardised cognitive testing. All participants
except controls must have a reliable informant who is
able to complete questionnaires for informant-related
scales and provide a background history in order to be
included. Further speciﬁc inclusion criteria for each
cohort are listed below under ‘Cohorts’. For the cohorts
including participants with dementia (groups 2, 4 and 6
below), we have included only participants with
mild-to-moderate dementia, as our experience is that
severely impaired participants are highly unlikely to
comply with the study protocol. Mild-to-moderate
dementia are deﬁned in this study as mini mental state
examination (MMSE) >12, though those with language
and/or semantic impairments (including the semantic
variant of FTD), for which the MMSE is an unsuitable
screening test, will be assessed using the Clinical
Dementia Rating Scale,42 with a score of 2 or less indi-
cating mild-to-moderate dementia.
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Exclusion criteria
Potential participants are excluded if they have a concur-
rent major psychiatric illness (except if this is depression
in the LLD cohort) or if they have a contraindication to
an MRI scan (such as a permanent pacemaker), are
unable to tolerate an MRI (due to claustrophobia) or if
they have a comorbidity that limits their ability to take
part in the study. Participants with Parkinson’s disease
(except in the DLB and PDD cohorts) or previous head
injury will also be excluded. Potential participants may
also be excluded if they have atypical or focal parenchy-
mal appearances on MRI which are not in keeping with
their diagnosis. Systemic inﬂammatory disease is also an
exclusion criterion, as are concurrent medications that
may affect study assessments (eg, oral steroids).
Cohorts
Participants are recruited into seven separate cohorts.
Unless otherwise stated, our intention is to recruit a
minimum of 16 participants (maximum 30) in each
diagnostic group, so providing 80% power to detect an
effect size of 1.0 between two groups. The cohorts
will be:
1. Healthy control participants, deﬁned as participants
with MMSE scores >26 and with an absence of (i)
regular memory symptoms, (ii) signs or symptoms
suggestive of dementia or (iii) unstable or signiﬁcant
medical illnesses.
2. Participants with AD who meet the diagnostic criteria
for probable AD as deﬁned by National Institute on
Aging-Alzheimer’s Association workgroups on diag-
nostic guidelines for AD.43
3. Participants with MCI, deﬁned as participants having
an MMSE >24 but with memory impairment beyond
that expected for age and education which does not
meet criteria for probable AD and is not explained
by another diagnosis.44
4. Participants with Lewy body dementia, meeting
either the 2005 consensus criteria for probable
DLB45 or the Movements Disorders Society clinical
diagnostic criteria for PDD.46
5. Participants with progressive supranuclear palsy ful-
ﬁlling the Litvan criteria, modiﬁed by a relaxation of
the falls criterion to falls within 3 years, rather than
1 year, as suggested by the NNIPPS-PSP study
group.47
6. FTD syndromes as deﬁned clinically by Rascovsky
et al48 and Gorno-Tempini et al.49
7. Five participants (to provide pilot data) with current
or a recent diagnosis of LLD as determined by the
DSM-IV criteria (American Psychiatric Association
2000).
Overview of protocol
Once written consent has been provided, participants
have a neuropsychological assessment using a test
battery described in detail below. The battery is tailored
to the cohort to which the participant belongs. All parti-
cipants also undergo an initial clinical assessment,
including the collection of clinical and demographic
information (including medication, smoking, alcohol
and education histories).
Participants then make between two and four visits for
imaging depending on their cohort. All participants have
Figure 1 Flow chart illustrating participants’ journey through the study. AD, Alzheimer’s disease; DLB, dementia with Lewy
bodies; FTD, frontotemporal dementia; LLD, late life depression; PDD, Parkinson’s disease dementia; PSP, progressive
supranuclear palsy.
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an MRI scan. Healthy control participants will undergo
one PET scan (either with [11C]PK11195 or [18F]
AV-1451) as will participants in the LLD cohort ([11C]
PK11195). MCI participants have three PET scans ([11C]
PK11195, [18F]AV-1451 and [11C]PiB). Participants in all
other cohorts will have two PET scans (for DLB cohort
[11C]PK11195 and [11C]PiB, for AD, PSP and FTD
cohorts [11C]PK11195 and [18F]AV-1451).
Venepuncture is carried out at the time of [11C]
PK11195 imaging in all participants to measure periph-
eral inﬂammatory and other degenerative markers.
Participants who provide additional consent will also
have a lumbar puncture for analysis of CSF, measuring
established and emerging candidate biomarkers of
neurodegeneration.
Each participant undergoes repeat neuropsychological
testing annually, for up to 3 years, to provide a longitu-
dinal assessment of cognitive function. Further details of
each of these stages are set out below.
Initial clinical assessment, neuropsychological battery and
informant questionnaires
At the initial visit, neuropsychological testing is under-
taken using the battery given in table 1: neuropsychological
testing. The neuropsychology battery differs slightly
between cohorts because of the disease-speciﬁc domains
we wish to examine. Clinical assessment is carried out
either at the same visit or on a day of attendance for
imaging. Neuropsychological follow-up using the same
battery of tests is undertaken annually for up to 3 years
from the date of initial assessment.
MRI imaging
MRI scanning will be carried out at the Wolfson Brain
Imaging Centre (WBIC) using 3 T Siemens scanners.
The following sequences are performed during the scan-
ning protocol:
1. Three-dimensional structural high-resolution
T1-weighted sequence examining for structural brain
abnormalities (176 slices of 1.0 mm thickness, ﬁrst
echo time (TE)=2.98 ms, repetition time (TR)
=2300 ms, ﬂip angle=9°, acquisition matrix 256×240;
voxel size=1×1×1 mm3).
2. Perfusion (pulsed arterial spin labelling) for blood
ﬂow (9 slices of 8.0 mm thickness, TE=13 ms,
TR=2500 ms, acquisition matrix 64×64; voxel
size=4×4×8 mm3, inversion time 1=700 ms, inversion
time 2=1800 ms).
3. Diffusor tensor imaging (DTI) to obtain fractional
anisotropy measures of white matter integrity
and gross axonal organisation (63 slices of
2.0 mm thickness, 63 diffusion directions, TE=
106 ms, TR=11 700 ms, b-value 1=0 s/mm2, b-value
2=1000 s/mm2, acquisition matrix 96×96; voxel
size=2×2×2 mm3).
4. Susceptibility-weighted imaging (SWI) to identify
microhaemorrhages, venous blood and iron depos-
ition (40 slices of 2.0 mm thickness, TE=20 ms,
TR=35 ms, ﬂip angle=17°, acquisition matrix
256×240; voxel size=1×1×2 mm3).
5. High-resolution hippocampal subﬁeld sequences
carried out in coronal T2 for smaller structural
changes in the hippocampus (20 slices of 2.0 mm
thickness, TR=6420 ms, ﬂip angle=160°, acquisition
matrix 512×408; voxel size=0.4×0.4×2 mm3).
6. Resting state functional MRI with pulse and breath-
ing monitored to examine ‘task-free’ functional brain
connectivity (34 slices of 3.8 mm thickness,
TE=13 ms, TR=2430 ms, ﬂip angle=90°, acquisition
matrix 64×64; voxel size=3.8×3.8×3.8 mm3, duration
11 min and 5 s).
7. T2 Fluid Attenuated Inversion Recovery (FLAIR) for
characterising periventricular lesions adjacent to the
sulci and white matter lesions and hyperintensities
(75 slices of 2 mm thickness, TE=132 ms,
TR=12 540 ms, ﬂip angle=120°, acquisition matrix
256×256; voxel size=0.9×0.9×2 mm3).
All images will be examined by a Consultant
Radiologist at CUH to exclude unexpected brain abnor-
malities in recruits. Participants with signiﬁcant abnor-
malities will be excluded from the study.
PET imaging
The radiotracers are produced at the WBIC
Radiopharmaceutical Chemistry laboratories. Both of
the 11C-labelled compounds as well as [18F]AV-1451
will be produced using the GE PETtrace cyclotron, a
16MeV proton and 8MeV deuteron accelerator. [11C]
PK11195 will be prepared using the ‘Disposable’ syn-
thesis system or GE TRACER laboratory FX-C
module, whereas [11C]PiB will be prepared using the
GE TRACER laboratory FX-C module. The produc-
tion of [18F]AV-1451 is based on the synthetic
methods developed by Avid Radiopharmaceuticals and
modiﬁed to use the GE TracerLab FX-FN synthesiser
at WBIC.
[11C]PK11195 PET
500 MBq [11C]PK11195 is injected intravenously over
30 s at the onset of a 75 min scan, with emission data
subsequently reconstructed into 55 contiguous time
frame images for kinetic analysis with the simpliﬁed ref-
erence tissue model.62
[11C]PiB PET
550 MBq of [11C]PiB is injected as a bolus and a PET
scan is performed 40–70 min postinjection, providing
image data suitable for subsequent standardised uptake
value ratio (SUVR) analysis.
[18F]AV-1451 PET
370 MBq of [18F]AV-1451 is injected intravenously over
30 s at the onset of a 90 min scan, with emission data
subsequently reconstructed into 58 contiguous time
frame images for kinetic analysis with the simpliﬁed ref-
erence tissue model.
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Table 1 Neuropsychological testing
Test name Format Purpose Cohort
Clinical assessment
UPDRS part III (motor subscale)50 Performed by study clinician Measure of Parkinsonism (motor aspects) All
Physical examination of eye movements Part of physical examination performed by study
clinician
Assessment of range and speed of eye movements All
Frontal assessment battery51 Assessment tool completed by study clinician Assessment of frontal lobe function FTD, PSP
PSP Rating Scale52 Assessment tool completed by study clinician Assessment of disease severity PSP
Praxis battery Part of physical examination performed by study
clinician
Assessment of manual ideomotor and copying ability All
Neuropsychological assessment
Addenbrooke’s cognitive examination—
revised53
Researcher administered structured test Multidomain cognitive screening tool All
INECO frontal screening54 Researcher administered structured test Assessment of frontal lobe function All
Trails A and B Researcher administered structured test Assessment of executive function All
Rey auditory verbal learning test Researcher administered test of learning, recall
and repetition of semantically unrelated words
Test of verbal episodic memory All except
PSP
Pyramids and palm trees Researcher administered, two alternative, forced
choice, picture based test
Assessment of semantic memory All
Cambridge Neuropsychological Test Automated Battery (CANTAB)
Simple reaction time55 Researcher administered computer task Information processing speed All
Paired associate learning56 Researcher administered computer task Assessment of visual episodic memory and learning All
Stockings of Cambridge57 Researcher administered, computer based spatial
planning task
Test of frontal lobe function All
Mental health questionnaires
Hospital Anxiety and Depression Scale A 14 item self-reported questionnaire Assessment of symptoms of anxiety and depression All
Geriatric Depression Scale A 30 item self-reported questionnaire Assessment of depressive symptoms All
Montgomery-Asberg Depression Rating
Scale58
A 10 item self-reported questionnaire Assessment of severity of depressive symptoms Controls,
LLD
Informant questionnaires
Cambridge Behavioural Inventory59 An 81 item carer-reported questionnaire Assessment of several behavioural abnormalities in
the everyday life including impulsivity and apathy
All except
controls
Clinical Dementia Rating Scale42 A carer-reported numerical scale Quantifying severity of dementia All except
controls
Bristol Activities of Daily Living Score A 20 item carer-reported questionnaire Measure of ability of person with dementia to carry out
activities of daily living
All except
controls
Neuropsychiatric inventory60 Researcher administered, carer-reported 13 item
screening tool
Assessment of psychopathology in people with brain
disorders
All except
controls
Clinical Assessment of Fluctuating
Confusion and Quality of Consciousness61
Researcher administered, carer-reported 9 item
screening tool
Assessment of conscious level and degree of
symptomatic arousal fluctuation
All except
controls
FTD, frontotemporal dementia; INECO, Instituto de Neurologia Cognitiva; LLD, late life depression; PSP, progressive supranuclear palsy; UPDRS, Unified Parkinson’s Disease Rating Scale.
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Blood samples
Eighty millilitres of blood is drawn at the time of [11C]
PK11195 PET scan. Basic inﬂammatory markers are
tested at the time of the sample with the remaining
blood being centrifuged to produce serum and plasma
samples to be stored at −80°C for future testing of
inﬂammatory and neurodegenerative markers. A sub-
group of participants also have blood immunophenotyp-
ing based on the availability of the technique to the
study. These participants will have blood samples ana-
lysed on the same day using ﬂow cytometry for
immune-phenotyping.
CSF samples
For those who consent to the additional CSF substudy,
CSF samples are obtained on a separate study visit. The
samples are obtained by a lumbar puncture and stored
at −80°C for future testing of inﬂammatory and neuro-
degenerative markers.
Analysis
Primary analysis of the PET data will compare each
subject group to controls based on [11C]PK11195 non-
displaceable binding potential (BPND) and [
11C]PIB
SUVR and/or [18F]AV-1451 BPND; BPND and SUVR
provide estimates of the density of ligand binding sites,
with BPND being a more speciﬁc measure. Likewise, MRI
data from patient groups will be compared to that of
controls and across groups. Analysis of PET and MRI
data use voxel-based and region of interest approaches.
We will also explore surface-based PET approaches in
order to improve signal-to-noise ratio in [11C]PK11195
analysis.63 Blood inﬂammatory markers and CSF mea-
sures of inﬂammation and τ, phosphor-τ, Aß and
α-synuclein will be compared using standard parametric
methods. Depending on initial analysis, between group
comparisons of imaging, cognitive and biomarker data
will be undertaken.
Neuropsychological test scores will be converted to
domain z scores for correlational analysis with imaging
data. Repeat measures will be normalised to control
scores at the relevant time point, and annualised change
scores correlated with baseline imaging changes to
determine predictors of decline, using univariate and
multivariate approaches as appropriate to determine key
predictors. Genetic analysis will be used to identify
known alleles associated with disease and for inﬂamma-
tion and exploratory analyses.
CURRENT STATUS AND DISSEMINATION
The study is Administration of Radioactive Substances
Advisory Committee (ARSAC) approved. The study is
already underway with active recruitment and data col-
lection. This will continue until Spring 2017. Early ana-
lyses are on-going and have been presented at recent
national and international conferences. Data will con-
tinue to be disseminated by presentation at national and
international conferences and by publication, predomin-
antly in journals of clinical neuroscience, neurology and
psychiatry. The cohort is part of the MRC funded
Dementias Platform UK collaboration.
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